BeStock  
Stocks › Biotechnology › OCS

Oculis OCS

US equityMarket cap rank #3648Biotechnology
$7.06 −$0.38 (-5.11%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $7.06 0.00%
Open$7.38
Prev close$7.44
Day range$6.98 – $7.43
Volume235.2K
Market cap$437.15M
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±1.9%last 10 reports
Closed higher6 of 1060% of the time
Best reaction+2.4%
Worst reaction-6.9%

Stock move on the day after each report

+1.5%2024/Q2-0.5%2024/Q3+0.5%2024/Q4+1.5%2025/Q1+0.3%2025/Q2-0.1%2025/Q3+0.5%2025/Q4-6.9%2026/Q1+2.4%2026/Q2-4.6%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q33 Nov 2026After Market±45.1%-4.59%Within range
2026/Q26 Aug 2026After Market–+2.42%–
2026/Q111 May 2026After Market±18.7%-6.86%Within range
2025/Q43 Mar 2026After Market–+0.54%–
2025/Q310 Nov 2025After Market–-0.10%–
2025/Q221 Aug 2025After Market–+0.28%–
2025/Q18 May 2025Pre Market–+1.52%–
2024/Q411 Mar 2025Pre Market–+0.55%–
2024/Q37 Nov 2024Pre Market–-0.53%–
2024/Q227 Aug 2024After Market–+1.51%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026 · reported in CHF

RevenueCHF 0.00
Operating profit-CHF 23.64M-16.5% YoY
Net profit-CHF 18.24M-8.2% YoY
Diluted EPS-CHF 0.30+6.3% YoY
Free cash flow-CHF 18.96M-40.0% YoY
Operating cash flow-CHF 18.96M

Revenue, last 8 quarters

CHF 0.0Dec '24CHF 0.0Mar '25CHF 0.0Jun '25CHF 0.0Sep '25CHF 0.0Dec '25CHF 0.0Mar '26CHF 0.0Jun '26CHF 0.0Sep '26

Net profit, last 8 quarters

CHF -28.7MDec '24CHF -33.2MMar '25CHF -25.4MJun '25CHF -16.9MSep '25CHF -23.5MDec '25CHF -28.9MMar '26CHF -10.0MJun '26CHF -18.2MSep '26

Profitability & balance sheet

Return on equity-47.5%
Return on assets-40.3%
Return on invested capital-47.2%
Current ratio10.41
Liabilities / assets10.1%
Cash & investmentsCHF 210.29M
Total debtCHF 1.98M
Net cash (debt)CHF 208.31M

Discussion

No comments yet — be the first to weigh in on OCS.

Sign in to join the discussion.

Scroll to Top